235 related articles for article (PubMed ID: 6897012)
1. In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations.
Ahmann FR; Meyskens FL; Moon TE; Durie BG; Salmon SE
Cancer Res; 1982 Nov; 42(11):4495-8. PubMed ID: 6897012
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
[TBL] [Abstract][Full Text] [Related]
3. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
Horikoshi N; Ogawa M; Inagaki J; Ezaki K; Inoue K; Okabe K; Nagata T; Aiba K; Domyo M
Gan To Kagaku Ryoho; 1982 Feb; 9(2):244-9. PubMed ID: 6897858
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer.
Casper ES; Gralla RJ; Kelsen DP; Natale RB; Sordillo P; Houghton A
Cancer Treat Rep; 1980; 64(2-3):345-7. PubMed ID: 6893294
[No Abstract] [Full Text] [Related]
5. Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.
Legha SS; Gutterman JU; Hall SW; Benjamin RS; Burgess MA; Valdivieso M; Bodey GP
Cancer Res; 1978 Nov; 38(11 Pt 1):3712-6. PubMed ID: 279397
[TBL] [Abstract][Full Text] [Related]
6. A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer.
Currie VE; Howard J; Wittes R
Cancer Clin Trials; 1981; 4(3):249-51. PubMed ID: 6895189
[TBL] [Abstract][Full Text] [Related]
7. Toxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide in exponential- and plateau-phase Chinese hamster cell cultures.
Wilson WR; Giesbrecht JL; Hill RP; Whitmore GF
Cancer Res; 1981 Jul; 41(7):2809-16. PubMed ID: 6894713
[TBL] [Abstract][Full Text] [Related]
8. New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay.
Salmon SE; Meyskens FL; Alberts DS; Soehnlen B; Young L
Cancer Treat Rep; 1981; 65(1-2):1-12. PubMed ID: 7226159
[TBL] [Abstract][Full Text] [Related]
9. Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.
Warrell RP; Straus DJ; Young CW
Cancer Treat Rep; 1980; 64(10-11):1157-8. PubMed ID: 6893952
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of 4'-(9-acridinylamino) methanesulfon-m-anisidide (m-AMSA, NSC 249992) on human tumors in nude mice.
Sordillo PP; Helson L; Lesser M
Cancer Clin Trials; 1980; 3(4):385-9. PubMed ID: 6893575
[TBL] [Abstract][Full Text] [Related]
11. Phase II. Evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced sarcoma.
Sordillo PP; Magill GB; Gralla RJ; Golbey RB
Cancer Treat Rep; 1980; 64(10-11):1129-30. PubMed ID: 6893950
[No Abstract] [Full Text] [Related]
12. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP
Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573
[TBL] [Abstract][Full Text] [Related]
13. Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia.
Odaimi M; Andersson BS; McCredie KB; Beran M
Cancer Res; 1986 Jul; 46(7):3330-3. PubMed ID: 3754787
[TBL] [Abstract][Full Text] [Related]
14. Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.
Arlin ZA; Sklaroff RB; Gee TS; Kempin SJ; Howard J; Clarkson BD; Young CW
Cancer Res; 1980 Sep; 40(9):3304-6. PubMed ID: 6933002
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic sensitivity of normal and leukemic hematopoietic progenitor cells to N-[4-(9-acridinylamino)-3-methoxyphenyl]-methanesulfonamide, a new anticancer agent.
Spiro TE; Socquet M; Delforge A; Stryckmans P
J Natl Cancer Inst; 1981 Apr; 66(4):615-8. PubMed ID: 6939909
[TBL] [Abstract][Full Text] [Related]
16. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
Woodcock TM; Schneider RJ; Young CW
Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
[TBL] [Abstract][Full Text] [Related]
17. Neurologic and cardiac rhythm abnormalities associated with 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) therapy.
Legha SS; Latreille J; McCredie KB; Bodey GP
Cancer Treat Rep; 1979; 63(11-12):2001-3. PubMed ID: 526933
[No Abstract] [Full Text] [Related]
18. Activity of 4'-(9-acridinylamino)methanesulfon-m-anisidide against Chinese hamster cells in multicellular spheroids.
Wilson WR; Whitmore GF; Hill RP
Cancer Res; 1981 Jul; 41(7):2817-22. PubMed ID: 7018670
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced colorectal carcinoma.
Carroll DS; Kemeny N; Lynch G; Wookcock T
Cancer Treat Rep; 1980; 64(10-11):1149-50. PubMed ID: 6893951
[No Abstract] [Full Text] [Related]
20. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer.
Legha SS; Blumenschein GR; Buzdar AU; Hortobagyi GN; Bodey GP
Cancer Treat Rep; 1979; 63(11-12):1961-4. PubMed ID: 526929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
